Argenica Therapeutics Ltd
AGN.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.7M
Close$
Share Statistics
| Market cap | $16.70 Million |
|---|---|
| Enterprise Value | $10.34 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 0.78 |
| Outstanding Shares | 128,456,712 |
Return
| Return on Equity | -144.61% |
|---|---|
| Return on Assets | -130.97% |
| Return on Invested Capital | -249.79% |
Valuation & Multiples
| P/E Ratio | -12.26 |
|---|---|
| PEG | 8.7 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.22 |
| Enterprise Value to EBIT | -0.7 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 2, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Argenica Therapeutics Ltd
7 employees
CEO: Liz Dallimore Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in ph...